ShockWave Medical Inc. (NASDAQ:SWAV) Relative Strength Index (RSI) is 63.85, with weekly volatility at 5.02% and ATR at 9.30. The SWAV stock’s 52-week price range has touched low of $41.77 and a $195.92 high. Intraday shares traded counted 0.51 million, which was -20.38% lower than its 30-day average trading volume of 422.72K. Its shares traded lower over the last trading session, losing -2.80% on 06/17/21. The shares fell to a low of $175.05 before closing at $188.27. SWAV’s previous close was $193.69 while the outstanding shares total 34.80M.
Investors have identified the Medical Devices company ShockWave Medical Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $6.38 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
ShockWave Medical Inc. (SWAV) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 233.11 million total, with 33.49 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 0.07 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SWAV sounds very interesting.
Is the stock of SWAV attractive?
In related news, Director, WATKINS FRANK T sold 2,000 shares of the company’s stock in a transaction that recorded on Jun 16. The sale was performed at an average price of 192.65, for a total value of 385,294. As the sale deal closes, the Chief Commercial Officer, Zacharias Isaac now sold 4,000 shares of the company’s stock, valued at 752,993. Also, Director, WATKINS FRANK T sold 2,000 shares of the company’s stock in a deal that was recorded on Jun 15. The shares were price at an average price of 188.34 per share, with a total market value of 376,680. Following this completion of acquisition, the Director, FRANCIS LAURA now holds 2,700 shares of the company’s stock, valued at 502,227. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.90%.
4 out of 6 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on ShockWave Medical Inc.. 0 analysts has assigned a Sell rating on the SWAV stock. The 12-month mean consensus price target for the company’s shares has been set at $176.20.